dc.contributor.author |
Farré López, Núria |
dc.contributor.author |
Mojón Álvarez, Diana |
dc.contributor.author |
Llagostera Martín, Marc |
dc.contributor.author |
Belarte Tornero, Laia Carla |
dc.contributor.author |
Calvo-Fernández, Alicia |
dc.contributor.author |
Vallés Gras, Ermengol |
dc.contributor.author |
Negrete, Alejandro |
dc.contributor.author |
Garcia Guimaraes, Marcos |
dc.contributor.author |
Bartolomé Fernández, Yolanda |
dc.contributor.author |
Fernández García, Camino |
dc.contributor.author |
García-Duran, Ana Beatriz |
dc.contributor.author |
Marrugat de la Iglesia, Jaume |
dc.contributor.author |
Vaquerizo Montilla, Beatriz |
dc.date.accessioned |
2021-10-19T07:08:09Z |
dc.date.available |
2021-10-19T07:08:09Z |
dc.date.issued |
2020 |
dc.identifier.citation |
Farré N, Mojón D, Llagostera M, Belarte-Tornero LC, Calvo-Fernández A, Vallés E, et al. Prolonged QT interval in SARS-CoV-2 infection: prevalence and prognosis. J Clin Med. 2020 Aug 21; 9(9): 2712. DOI: 10.3390/jcm9092712 |
dc.identifier.issn |
2077-0383 |
dc.identifier.uri |
http://hdl.handle.net/10230/48695 |
dc.description.abstract |
Background: The prognostic value of a prolonged QT interval in SARS-Cov2 infection is not well known. Objective: To determine whether the presence of a prolonged QT on admission is an independent factor for mortality in SARS-Cov2 hospitalized patients. Methods: Single-center cohort of 623 consecutive patients with positive polymerase-chain-reaction test (PCR) to SARS Cov2, recruited from 27 February to 7 April 2020. An electrocardiogram was taken on these patients within the first 48 h after diagnosis and before the administration of any medication with a known effect on QT interval. A prolonged QT interval was defined as a corrected QT (QTc) interval >480 milliseconds. Patients were followed up with until 10 May 2020. Results: Sixty-one patients (9.8%) had prolonged QTc and only 3.2% had a baseline QTc > 500 milliseconds. Patients with prolonged QTc were older, had more comorbidities, and higher levels of immune-inflammatory markers. There were no episodes of ventricular tachycardia or ventricular fibrillation during hospitalization. All-cause death was higher in patients with prolonged QTc (41.0% vs. 8.7%, p < 0.001, multivariable HR 2.68 (1.58-4.55), p < 0.001). Conclusions: Almost 10% of patients with COVID-19 infection have a prolonged QTc interval on admission. A prolonged QTc was independently associated with a higher mortality even after adjustment for age, comorbidities, and treatment with hydroxychloroquine and azithromycin. An electrocardiogram should be included on admission to identify high-risk SARS-CoV-2 patients. |
dc.format.mimetype |
application/pdf |
dc.language.iso |
eng |
dc.publisher |
MDPI |
dc.rights |
Copyright © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
dc.rights.uri |
http://creativecommons.org/licenses/by/4.0/ |
dc.title |
Prolonged QT interval in SARS-CoV-2 infection: prevalence and prognosis |
dc.type |
info:eu-repo/semantics/article |
dc.identifier.doi |
http://dx.doi.org/10.3390/jcm9092712 |
dc.subject.keyword |
COVID-19 |
dc.subject.keyword |
QT interval |
dc.subject.keyword |
Azithromycin |
dc.subject.keyword |
Death |
dc.subject.keyword |
Hydroxychloroquine |
dc.subject.keyword |
Prognosis |
dc.rights.accessRights |
info:eu-repo/semantics/openAccess |
dc.type.version |
info:eu-repo/semantics/publishedVersion |